Ticker Symbol: DNLI

Denali Therapeutics Inc

$50.43 - 20-12-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001714899

Company Profile

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.

Sector: Manufacturing

Industry: Biological Product (except Diagnostic) Manufacturing

Standard Industrial Classification Code (SIC code): 2836

Address: 161 Oyster Point Blvd

Website: www.denalitherapeutics.com

CEO: Ryan Watts

Tags:

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing

Pricing

Last Updated: October 13, 2023 03:00 PM EST

Previous Close: $20.76

Change: $0.25 ( 1.22%)

Days Range: $20.10 - $20.76

Beta: 1.35

52wk. High: $33.31

52wk. Low: $18.07

Ytd. Change -25.03%

50 Day Moving Average: $21.78

200 Day Moving Average: $26.09

Shares Outstanding: 137400000

Valuation

Market Cap: 285.2B

PE Ratio: -21.58

EPS (TTM): -0.9618

Dividends

Dividend Per Share (TTM): -

Dividend Yield (TTM): 0.00%

Ex-Dividend Date: N/A